Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$15.36
+2.7%
$14.02
$5.00
$20.21
$159.13M0.59849,517 shs22,080 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$18.50
+1.0%
$16.41
$13.46
$31.04
$525.40M0.94509,741 shs309,481 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
0.0%
$29.36
$4.30
$31.70
$497.22MN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$4.96
-2.2%
$3.82
$2.02
$5.57
$490.24M0.371.90 million shs1.75 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-3.30%-2.10%-2.42%-20.14%+146.78%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-4.39%+1.22%+14.72%+27.33%-14.56%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%-0.02%-0.02%-0.02%+2,935,499,900.00%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
+4.11%+6.07%+26.75%+94.25%+82.37%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biodesix, Inc. stock logo
BDSX
Biodesix
$15.36
+2.7%
$14.02
$5.00
$20.21
$159.13M0.59849,517 shs22,080 shs
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$18.50
+1.0%
$16.41
$13.46
$31.04
$525.40M0.94509,741 shs309,481 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
0.0%
$29.36
$4.30
$31.70
$497.22MN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$4.96
-2.2%
$3.82
$2.02
$5.57
$490.24M0.371.90 million shs1.75 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biodesix, Inc. stock logo
BDSX
Biodesix
-3.30%-2.10%-2.42%-20.14%+146.78%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-4.39%+1.22%+14.72%+27.33%-14.56%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%-0.02%-0.02%-0.02%+2,935,499,900.00%
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
+4.11%+6.07%+26.75%+94.25%+82.37%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biodesix, Inc. stock logo
BDSX
Biodesix
2.33
Hold$22.0043.23% Upside
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
2.20
Hold$27.0045.95% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
2.60
Moderate Buy$7.2546.17% Upside

Current Analyst Ratings Breakdown

Latest BDSX, FLGT, TOI, and MCTA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/8/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Boost Price TargetBuy$7.00 ➝ $8.00
5/18/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
DowngradeSell (D-)Sell (E+)
5/5/2026
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
Reiterated RatingNeutral$30.00 ➝ $15.00
5/5/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Boost Price TargetBuy$20.00 ➝ $22.00
5/4/2026
Biodesix, Inc. stock logo
BDSX
Biodesix
Reiterated RatingSell (D-)
4/20/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Reiterated RatingSell (D-)
3/13/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Boost Price TargetBuy$6.00 ➝ $8.00
3/9/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Reiterated RatingBuy$7.00
3/9/2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
Reiterated RatingBuy$5.00
(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biodesix, Inc. stock logo
BDSX
Biodesix
$88.50M1.80N/AN/A($0.31) per share-49.55
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
$322.67M1.63N/AN/A$35.80 per share0.52
Charming Medical Ltd stock logo
MCTA
Charming Medical
$5.42M91.68N/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
$545.76M0.90N/AN/A($0.16) per share-31.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biodesix, Inc. stock logo
BDSX
Biodesix
-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$60.61M-$0.37N/AN/AN/A-7.42%N/A-24.68%8/12/2026 (Estimated)

Latest BDSX, FLGT, TOI, and MCTA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.07-$0.02+$0.05-$0.02$142.10 million$147.44 million
5/4/2026Q1 2026
Biodesix, Inc. stock logo
BDSX
Biodesix
-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million
3/12/2026Q4 2025
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
-$0.08-$0.06+$0.02-$0.06$139.78 million$141.96 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biodesix, Inc. stock logo
BDSX
Biodesix
N/AN/AN/AN/AN/A
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biodesix, Inc. stock logo
BDSX
Biodesix
5.09
2.82
2.82
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
N/A
5.31
5.31
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
N/A
1.47
1.17

Institutional Ownership

CompanyInstitutional Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
20.96%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
48.06%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
36.86%

Insider Ownership

CompanyInsider Ownership
Biodesix, Inc. stock logo
BDSX
Biodesix
23.20%
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
36.18%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
8.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biodesix, Inc. stock logo
BDSX
Biodesix
22010.36 million7.95 millionNo Data
Fulgent Genetics, Inc. stock logo
FLGT
Fulgent Genetics
1,31528.40 million18.13 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
The Oncology Institute, Inc. stock logo
TOI
Oncology Institute
66098.84 million90.44 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biodesix stock logo

Biodesix NASDAQ:BDSX

$15.36 +0.41 (+2.74%)
Closing price 04:00 PM Eastern
Extended Trading
$15.28 -0.07 (-0.49%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Fulgent Genetics stock logo

Fulgent Genetics NASDAQ:FLGT

$18.50 +0.19 (+1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$18.52 +0.02 (+0.08%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 -0.01 (-0.02%)
As of 06/8/2026

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Oncology Institute stock logo

Oncology Institute NASDAQ:TOI

$4.96 -0.11 (-2.17%)
Closing price 04:00 PM Eastern
Extended Trading
$4.96 0.00 (-0.10%)
As of 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.